Lilly To Focus Mainly On Pipeline Development As It Faces Steep Patent Cliff
This article was originally published in The Pink Sheet Daily
Executive Summary
With generic competition around the corner for blockbusters like Zyprexa, Lilly can't count on many more quarters like the past one's 16 percent net income growth.
You may also be interested in...
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
Lilly Partners With Marcadia For Injectable Pens To Treat Hypoglycemia
Already a leader in emergency kits, Lilly will support trials on a simpler device that doesn't require complex preparation.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.